Mitochondrial and NAD+ Research Faces a Human Evidence Test

On September 30, 2026, L.E.K. Consulting published “Longevity Therapeutics Comes of Age” by Stephen Roper and Simon Middleton. The industry analysis assessed a shift toward human-anchored discovery and development through recognized age-related diseases.

Human clinical benefit remains the central test

L.E.K.’s central conclusion is that longevity therapeutics remains clinically unproven, with reproducible benefit in people as the deciding test. It identifies mitochondrial dysfunction and NAD+ biology alongside cellular senescence and inflammaging as active areas of development. The report’s emphasis is on translating an aging-related mechanism into a measurable result through a recognized disease. For healthspan research, that makes clinical outcomes the central issue rather than the prominence of a target in the development pipeline.

The report maps development rather than conducting an experiment

Evidence type: This is an industry analysis, not an in vitro study, animal-model experiment or human trial; it discusses programmes in human clinical development.

This distinction determines how to read the report. L.E.K. assembles a picture of therapeutic activity using named programmes, their clinical stages and anticipated milestones. Its account is a map of development rather than a set of results from a single experimental population.

The appropriate unit of attention is therefore the individual programme and the disease through which it is being tested. A broad target category helps organize the field, while a specific clinical endpoint gives a programme a defined test. That separation is useful when reading claims about mitochondrial approaches or NAD+ biology.

Recognized diseases give programmes a defined clinical test

L.E.K. calls development through an age-related disease “a strategic sequencing choice.” The strategy allows earlier proof-of-concept testing with disease-specific endpoints rather than requiring long-duration lifespan studies. It reflects the analysis’s wider emphasis on human-anchored discovery and clearer mechanisms.

The practical difference is the question a programme must answer. Instead of making a general case that its target matters to aging, it is tested against an outcome in a specified disease. A result can then be discussed in relation to that condition and the endpoint used to assess it.

That approach gives readers a clearer starting point for separating healthspan research from life-extension claims. It also makes the choice of disease and endpoint part of the scientific story rather than background detail.

The named programmes occupy different clinical stages

BioAge Labs’ BGE-102 is described by L.E.K. as a Phase 2 oral NLRP3 inhibitor. The analysis places NLRP3 alongside IL-11 within its discussion of inflammaging. This programme gives the report a concrete example of development in an area where it expects near-term clinical readouts.

Stealth BioTherapeutics’ elamipretide is described as a Phase 3 programme related to mitochondrial dysfunction. L.E.K. expects pivotal data in dry age-related macular degeneration in 2027 and 2028. The disease indication is important because it specifies the setting for the projected clinical evidence.

Life Biosciences’ ER-100 is described as a Phase 1 partial epigenetic reprogramming programme. L.E.K. expects an initial human safety readout over the same period. This places reprogramming within the report’s development map while identifying the particular kind of readout being anticipated.

Together, these examples show why a pipeline should be read programme by programme. The molecular target tells readers which area of biology is being addressed. The clinical phase describes where the programme sits in development. The indication and expected readout identify the question the upcoming data are meant to address.

Near-term readouts are concentrated in selected areas

L.E.K. identifies cellular senescence and partial epigenetic reprogramming as additional areas of activity alongside mitochondrial dysfunction and NAD+ biology. It says near-term clinical readouts are concentrated in inflammaging, mitochondrial dysfunction and cellular senescence. That is a statement about the current development pipeline and its expected flow of evidence.

For a reader interested in NAD+ biology, the useful question is which specific human result supports a claim. For a reader following mitochondrial approaches, the same question should be tied to the relevant programme and disease. The target name organizes the research; the outcome is what the clinical test is intended to establish.

The analysis leaves important evidence gaps

L.E.K.’s own caveats provide the most useful checks on its assessment. These are the distinctions that matter when interpreting a sector analysis or a claim about an emerging longevity intervention:

• Disease-specific scope: L.E.K. presents recognized diseases as a route to earlier clinical evidence. An improvement in a disease endpoint would need to be interpreted within that setting. It would not by itself establish that the intervention extends human lifespan or improves healthspan broadly. Keep the disease claim separate from any wider aging claim.
• Clinical stage does not establish efficacy: L.E.K. recounts that Unity Biotechnology’s UBX0101 senolytic programme failed to show benefit in painful knee osteoarthritis. It also reports that resTORbio’s RTB101 missed its Phase 3 primary endpoint in respiratory illness in older adults. Those are programme-specific setbacks rather than a basis for dismissing every intervention in a target class. Assess the reported outcome instead of treating the phase label as a verdict.
• Animal findings need human validation: L.E.K. cautions that results in animal models may not translate to people. When a claim rests on animal evidence, keep that evidence category visible. The key follow-up is a human result linked to a meaningful clinical outcome.
• Biomarker changes need clinical interpretation: The report flags uncertainty about how epigenetic clocks and proteomic age signatures relate to clinically meaningful benefit. A biological-age measurement and a health outcome are different claims. Look for evidence connecting the measurement to the benefit being advertised rather than accepting a changed age score as the outcome.
• Forecasts are not results: The milestones expected in 2027 and 2028 are projections. The analysis supplies no numerical efficacy or safety results for those upcoming readouts. An anticipated initial safety report and projected pivotal disease data should be tracked according to their stated purpose, then assessed when results become available.
• Funding measures market activity rather than therapeutic success: L.E.K. estimates financing of US$8.5 billion in 2024 and approximately US$5.7 billion in 2025. These totals cover therapeutics and discovery platforms as well as diagnostics and consumer-facing services. The analysis also says capital became more concentrated in 2025 and warns that large individual financings or public-market transactions can affect annual totals. Use these figures as broad sector context rather than as a tally of drug-development investment or clinical progress.
• The approval pathway is still incomplete: L.E.K. describes a clearer regulatory direction but says neither the TAME framework nor the ICD-11 classification it discusses provides a complete approval pathway. Treat discussion of a regulatory framework separately from evidence that a particular programme has demonstrated a clinical benefit.
• A target map is not a treatment recommendation: The report identifies research areas rather than establishing a personal reason to use an NAD+-related product or another emerging intervention. For individual decisions about supplements or therapies, the appropriate next step is qualified care rather than extrapolation from a sector overview.

A practical way to read the next announcement is to identify its evidence type, the population studied and the outcome measured. Then check whether the headline describes that outcome or substitutes a broader promise about aging. A structured approach to weighing the evidence behind longevity claims keeps these questions together without turning a research update into individual treatment advice.

The next test is reproducible benefit in people

The next logical phase is to use the disease-specific readouts expected through 2027 and 2028 to assess safety and reproducible clinical benefit, then determine whether successful programmes justify broader healthspan research.

How AgeAmaze helps

Mitochondrial and NAD+ target lists can make experimental approaches sound ready for use, while AgeAmaze puts their evidence level and unresolved questions in view. Overstated therapy claims make emerging interventions difficult to judge, so the publication explains longevity science for research-minded adults seeking a grounded understanding rather than a treatment promise.

Read the research

Sources

1. Longevity Therapeutics Comes of Age